Central monoamine metabolism in Parkinson's disease.
D000328:Adult; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism*; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D011339:Probenecid / Q000627:therapeutic use*; D012701:Serotonin / Q000378:metabolism*
D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D011339:Probenecid; D004298:Dopamine